Drugs in Dev. Oncology
Discovery Platform
Netherlands 
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Elevation Oncology
Deal Size : $368.0 million
Deal Type : Licensing Agreement
Elevation Lifts HER3 ADC Toward Clinic with $368M Synaffix Deal
Details : Under the licensing agreement, Synaffix grants Elevation global access to its ADC technology platform, enabling the transformation of antibodies into differentiated ADCs with best-in-class potential.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Elevation Oncology
Deal Size : $368.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : $1,581.0 million
Deal Type : Collaboration
Gilead and Merus Collaborates to Discover Antibody-Based Trispecific T-Cell Engagers
Details : The collaboration aims to use Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $56.0 million
June 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : $1,581.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sotio
Deal Size : $740.0 million
Deal Type : Licensing Agreement
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
Details : Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sotio
Deal Size : $740.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : M Ventures
Deal Size : $24.0 million
Deal Type : Financing
Details : The funds will be used to advance a proprietary drug discovery portfolio in oncology and establish a versatile and robust platform to address the target space broadly across multiple indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : M Ventures
Deal Size : $24.0 million
Deal Type : Financing
Reset All
